Vertex Pharmaceuticals Incorporated VRTX
550.87 USD +3.78 (+0.69%)
At closeNov 10, 2026, 4:01 AM EST
549.18 -1.69 -0.31%
Pre-market · Nov 10, 4:01 AM ET
538.48 Day range 555.99
410.50 52-week range 568.67
- YTD
- +21.51%
- 1 year
- +34.53%
News
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
defenseworld.net Associated Banc Corp Purchases 5,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and…
benzinga.com Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626 Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $617 to $626.
benzinga.com Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.
defenseworld.net Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by AIA Group Ltd AIA Group Ltd reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in the undefined quarter, according to its most recent disclosure with the Securities and…
fxempire.com Vertex Pharmaceuticals Thrives on Higher Sales and Guidance VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
defenseworld.net Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTX Aware Super Pty Ltd as trustee of Aware Super boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 121.9% in the undefined quarter, according to the company in its…
benzinga.com Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725 Goldman Sachs analyst Salveen Richter maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $654 to $725.
benzinga.com Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660 Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $665 to $660.- benzinga.com Scotiabank Maintains Sector Outperform on Vertex Pharmaceuticals, Raises Price Target to $660 Scotiabank analyst Louise Chen maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Outperform and raises the price target from $558 to $660.
zacks.com CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.- benzinga.com UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640 UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $615 to $640.
zacks.com VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.- benzinga.com TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $575 TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $550 to $575.
benzinga.com Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $650 Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $550 to $650.- benzinga.com RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $600 RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $576 to $600.
benzinga.com Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for TEM, TWLO, UPWK, MRSH and PLTR; cut MRVL and AAPL targets, with upgrades for TWLO and MRSH.
benzinga.com Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Mixed as Trump Touts Iran Settlement Hopes — AAPL, PLTR, AMD in Focus (UPDATED) U.S. stocks were mixed on Tuesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different directions.
benzinga.com Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.
benzinga.com Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results Vertex missed Q3 EPS estimates but beat sales, raised FY2026 guidance, and shares rose 2.7% as analysts lifted price targets.- benzinga.com Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $563 Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $500 to $563.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $619 Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $595 to $619.
benzinga.com Vertex Pharmaceuticals Q3 2026 Earnings Call Transcript Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Vertex Pharmaceuticals Q3 Adj. EPS $4.76 Misses $4.82 Estimate, Sales $3.441B Beat $3.417B Estimate Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.76 per share which missed the analyst consensus estimate of $4.82 by 1.24 percent. This is a 0.83 percent decrease over earnings…
benzinga.com Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $13.100B-$13.200B to $13.150B-$13.250B vs $13.245B Est Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $13.100 billion-$13.200 billion to $13.150 billion-$13.250 billion vs $13.245 billion estimate.
benzinga.com Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
benzinga.com Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 4.68% on an annualized basis producing an average annual return of 13.63%. Currently, Vertex Pharmaceuticals…- benzinga.com Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30 - Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN…
finance.biggo.com Biotech ETFs Hold Up as Hims-Lilly GLP-1 Pact and Summit's FDA Verdict Near Biotech ETFs are outperforming the broader market ahead of a Nov. 14 FDA target date for Summit Therapeutics' ivonescimab plus chemotherapy ...ainvest.com ACAD Plunges 15.66% on Q3 Earnings Shock: Is the Floor Near? Acadia Pharmaceuticals (ACAD) plunged 15.66% after Q3 2026 earnings, triggering a massive repricing of its near-term outlook.
finance.sina.com.cn 福泰制药收涨0.69%，成交额6.66亿美元 该公司拥有七种获批药物：五种用于治疗囊性纤维化（CF）的根本病因，一种用于治疗严重镰状细胞病（SCD）和输血依赖性β地中海贫血（TDT），一种用于治疗中度至重度急性疼痛。其产品线包括CF、SCD、β地中海贫血、急性和周围神经性疼痛、载脂蛋白L1（APOL1）介导的肾脏疾病、免疫球蛋白A（IgA）肾病和其他自身免疫性肾脏疾病和血细胞减少症、1型糖尿病、1型肌强直性营养不良症和常染色体显性多囊肾病的临…seekingalpha.com Why Capital Is Rotating Into Healthcare For 2027 Discover why healthcare ETFs like VHT are gaining appeal as defensive plays, with strong spending and earnings trends.
finance.yahoo.com Here is Why Growth Investors Should Buy Vertex (VERX) Now Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's ...
ad-hoc-news.de Vertex stock faces November 30 FDA test after Q3 growth Vertex Pharmaceuticals reported stronger third-quarter sales and lifted its full-year outlook on November 2, while preparing ...
ziare.com TrevIQ | Analiză rezultate trimestriale (T3 2026). Profit surpriză și prognoză de venituri majorată Moderna a raportat pentru T3 2026 rezultate mult peste așteptări, revenind pe profit după o creștere a veniturilor de 29% YoY ...
newswire.ca Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m.
msn.com Hims-Eli Lilly GLP-1 deal meets Summit’s FDA gamble: Which biotech ETFs stand to gain? Biotech ETFs face a pivotal week as Summit Therapeutics SMMT approaches a key FDA decision, while fresh drug-development ...